Genenta Science S.p.A. (NASDAQ:GNTA) Sees Large Growth in Short Interest

Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 11,600 shares, a growth of 152.2% from the September 30th total of 4,600 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is presently 0.9 days.

Genenta Science Stock Performance

NASDAQ GNTA traded down $0.13 during trading on Friday, hitting $5.22. The company's stock had a trading volume of 8,137 shares, compared to its average volume of 29,437. Genenta Science has a 52 week low of $2.20 and a 52 week high of $7.28. The firm has a 50 day moving average price of $4.49 and a 200 day moving average price of $3.87.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $25.00 target price on shares of Genenta Science in a report on Wednesday, October 2nd.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. acquired a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent filing with the Securities and Exchange Commission. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.